BTIG analyst Mark Massaro lowered the firm’s price target on GeneDx (WGS) to $100 from $115 but keeps a Buy rating on the shares. The stock declined by a staggering 43% following the company’s Q1 results, which is a major overreaction that was mainly driven by mother nature and overly bullish buyside expectations, the analyst tells investors in a research note. With the major stock pullback, shares of GeneDx trade at 4 times the firm’s 2026 rev estimates, which marks an attractive entry point for investors, BTIG adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target lowered to $78 from $105 at Wells Fargo
- GeneDx Reports Strong Q1 2025 Growth and Expansion Plans
- GeneDx Holdings Corp. Reports Strong Earnings and Strategic Growth
- GeneDx Holdings: Strong Growth Potential and Strategic Acquisitions Drive Buy Rating
- GeneDx earnings selloff a buying opportunity, says Craig-Hallum
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue